Funding agencies: This study was funded by XenoPort, Inc.
Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease
Article first published online: 13 DEC 2013
Copyright © 2013 Movement Disorder Society
Volume 29, Issue 1, pages 75–82, January 2014
How to Cite
LeWitt, P. A., Huff, F. J., Hauser, R. A., Chen, D., Lissin, D., Zomorodi, K. and Cundy, K. C. (2014), Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov. Disord., 29: 75–82. doi: 10.1002/mds.25742
Relevant conflicts of interest/financial disclosures: Drs. LeWitt and Hauser have been clinical investigators for the study sponsor (XenoPort) and have also served as consultants advising the clinical trial program. Dr. Huff is a consultant (and previously an employee of XenoPort). He owns stock and stock options in XenoPort. Drs Chen, Lissin, Zomorodi, and Cundy are employees and stockholders of XenoPort.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 23 JAN 2014
- Article first published online: 13 DEC 2013
- Manuscript Accepted: 1 OCT 2013
- Manuscript Revised: 25 SEP 2013
- Manuscript Received: 1 MAY 2013
- Parkinson's disease;
- motor fluctuations;
The objective of this study was to assess the efficacy, safety, and pharmacokinetics of XP21279-carbidopa in patients with Parkinson's disease who experience motor fluctuations compared with immediate-release carbidopa-levodopa tablets. XP21279 is a levodopa prodrug that is actively absorbed by high-capacity nutrient transporters expressed throughout the gastrointestinal tract and then rapidly converted to levodopa by carboxylesterases. XP21279-carbidopa sustained-release bilayer tablets were developed to overcome pharmacokinetic limitations of levodopa by providing more continuous exposure. Patients with motor fluctuations who required carbidopa-levodopa four or five times daily were optimized for 2 weeks each on carbidopa-levodopa four or five times daily and XP21279-carbidopa three times daily in a randomized sequence. Next, they received each optimized treatment for 2 weeks in a double-blind/double-dummy, randomized sequence. The primary outcome measure was change from baseline in daily off time at the end of each double-blind treatment period. All patients at 2 sites underwent pharmacokinetic analyses. Twenty-eight of 35 enrolled patients completed both double-blind treatments. The mean total daily off time was reduced from baseline by a mean (± standard error) of 2.7 hours (± 0.48 hours) for immediate-release carbidopa-levodopa and 3.0 hours (± 0.57 hours) for XP21279-carbidopa (P = 0.49). Among 11 patients who completed pharmacokinetic sampling on each optimized treatment, the percentage deviation from the mean levodopa concentration was lower (P < 0.05) for XP21279-carbidopa than carbidopa-levodopa. Both treatments had a similar incidence of new or worsening dyskinesias. XP21279-carbidopa administered three times daily produced a reduction in off time similar to that of carbidopa-levodopa administered four or five times daily, and the difference was not statistically significant. XP21279-carbidopa significantly reduced variability in levodopa concentrations compared with carbidopa-levodopa. © 2013 International Parkinson and Movement Disorder Society